Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
RevOpsis and Kemwell Form Manufacturing Partnership for nAMD
RevOpsis Therapeutics and Kemwell Biopharma have forged a strategic manufacturing partnership aimed at accelerating the development of RO-104, a pioneering tri-specific biologic designed by RevOpsis for treating neovascular age-related macular degeneration (nAMD). Neovascular age-related macular degeneration (nAMD) is a progressive…
Oculis’ Licaminlimab Shows Promise in Phase 2B Trial for DED
Oculis Holding announced positive topline results from its phase 2b RELIEF trial, shedding light on the efficacy of licaminlimab, an innovative anti-TNFα biologic eye drop, in addressing dry eye disease (DED). Licaminlimab’s established dual mechanism of action, boasting both anti-inflammatory…
Study Identifies Risk Factors for Hydroxychloroquine Retinopathy
A recent study published online in JAMA Network Open sheds light on factors associated with an increased risk for hydroxychloroquine retinopathy. The research, led by April M. Jorge, M.D., from Massachusetts General Hospital in Boston, identifies crucial risk factors beyond…
What is X-Linked Retinitis Pigmentosa
Retinitis pigmentosa (RP) describes a group of rare genetic eye diseases that damage light-sensitive cells in the retina, leading to loss of sight over time. In about 10% of RP cases, the non-working gene is passed down from the mother…
Metformin Found Ineffective Against Geographic Atrophy
In the quest to find effective treatments for eye diseases, the METformin for the MINimization of Geographic Atrophy Progression (METforMIN) trial sought to evaluate the efficacy of oral metformin in slowing the progression of geographic atrophy (GA) and its effects…
Preseptal and Orbital Cellulitis | OBN
Preseptal cellulitis (periorbital cellulitis) is infection of the eyelid and surrounding skin anterior to the orbital septum. Orbital cellulitis is infection of the orbital tissues posterior to the orbital septum. Either can be caused by an external focus of infection (eg, a wound),…
Nordic Pharma Introduces Lacrifill Canalicular Gel for Dry Eye
Nordic Pharma announced the commercial launch of Lacrifill Canalicular Gel, aimed at addressing dry eye disease in the United States. This novel therapy, Lacrifill, is a cross-linked hyaluronic acid derivative that has received clearance from the FDA. Its primary function…
J&J’s Nipocalimab Shows Promising Results in Sjögren’s Disease
Johnson & Johnson announced promising topline results from its Phase 3 VIVACITY study evaluating nipocalimab in adults with generalized myasthenia gravis (gMG), alongside findings from the Phase 2 DAHLIAS study in adults with Sjögren’s disease (SjD). Nipocalimab, an investigational treatment,…
New Device Targets Dry Eye and Beyond with Thermal Imaging
A groundbreaking innovation in ocular health assessment is on the horizon, as a new University of Waterloo spinoff company, ThermOcular AI, unveils its pioneering approach to eye temperature monitoring. Transforming Ocular Diagnostics Founded by vision science and engineering researchers from…
Teprotumumab Shows Long-Lasting Benefits for TED Patients
Research presented at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Massachusetts, and published in the journal Thyroid, indicates that most patients with thyroid eye disease (TED) treated with teprotumumab did not require additional treatments nearly two years later.…